Compare iShares MSCI Taiwan ETF (EWT) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs 10X Genomics Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.66 (market cap $12.74B), while 10X Genomics Inc trades at $79.3 (market cap $10.07B). The key difference: iShares MSCI Taiwan ETF is the larger of the two by market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and 10X Genomics Inc for 92 Days on average.
| EWT | TXG | |
|---|---|---|
Market Cap | $12.74B | $10.07B |
Volume | 8,470,920 | 5,657,286 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $97.74 |
52-Week Low | $60.03 | $11.48 |
Typical Hold Time | 52 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT, the iShares MSCI Taiwan ETF, trades at $116.24, down 1.16% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF is heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights strong institutional interest and substantial Taiwanese corporate investments in U.S. AI infrastructure, though geopolitical tensions with China present ongoing risks.
The outlook for EWT is positive due to Taiwan's pivotal role in AI and semiconductor supply chains, supported by robust capital expenditure plans from key holdings. However, elevated geopolitical risks and sector concentration require careful monitoring. Upside potential hinges on sustained AI demand, while downside risks include cross-strait tensions and global tech volatility.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
